Investors Have Been Waiting to Buy the Dip in This Hot Biopharma Stock
Jazz Pharmaceuticals (JAZZ) is a specialty biopharma company focused on neuroscience and oncology. JAZZ exhibits strong technical momentum. Shares are up nearly 50% over the past year. The stock maintains a 100% “Buy” technical opinion from Barchart. Wall Street sentiment is bullish with multiple “Strong Buy” ratings and price targets...
Barchart ·